COLORADO SPRINGS, Colo.,
Nov. 8, 2013 /PRNewswire/ -- Endocan
Corporation (NASDAQ OTC: ENDO), a U.S. Company specializing in
cannabis and cannabinoid formulation-based health and wellness
solutions, is pleased to announce that Robert Kane, CFO and Sr. VP of Business
Development, speaks to StockRadio.com with respect to Endocan's
latest developments and overall strategy to make 2014 a historic
year.
The interview is available at http://thestockradio.com and will
also be posted on the Company's social media outlets:
Facebook, Twitter, and Google+.
"Endocan is a young company progressing quickly in a dynamic and
highly profitable industry. Extra time and effort has been
placed on making sure every step is being executed properly with a
full understanding of the regulatory and constantly changing
environment in which we operate, with a recent focus on our major
branding campaign. We appreciate TheStockRadio.Com and its
audience for taking their valuable time to listen to an overview of
our patient-focused story, which is still available at
TheStockRadio.Com website," stated Robert
Kane, CFO & Sr. VP of Business Development, Endocan
Corporation.
About The StockRadio.Com
The StockRadio.com is a small-cap research and investment
commentary provider. TheStockRadio.com strives to provide a
balanced view of many promising small-cap companies that would
otherwise fall under the radar of the typical Wall Street investor.
We provide investors with an excellent first step in their research
and due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
information on TheStockRadio, please visit
http://thestockradio.com.
About Endocan Corporation
The brand name Endocan™ was
chosen by the Board of Directors as a direct reference to the
endocannabinoid system of the human body. The endocannabinoid
system is a group of neuromodulatory compounds and their receptors
that are involved in a variety of fundamental physiological
processes including pain-sensation, immune function, stress, sleep,
mood, appetite, and memory. Cannabinoids from plants, including
those found in the Cannabis genus, as well as those autonomously
produced within living biological systems, work together in the
operation of the endocannabinoid system. The modulation of this
system is the basis for cannabinoid-based medical treatments to
assist patients to improve their health and well-being.
Endocan Corporation (FKA The X-Change Corporation and as XCHC)
is currently developing new natural cannabis-based products based
on innovative formulations to utilize the unique and potent
benefits of the cannabis and hemp plants. Medicinal properties of
cannabis and hemp have been known and applied for thousands of
years. With the aid of scientific research, Endocan Corporation is
translating such knowledge into development of effective
cannabinoid formulation-based health and wellness solutions as well
as cosmeceutical, nutraceutical, and food brands throughout the
world. The Company's health and wellness, nutritional, and
cosmetics lines will address personal needs and will evolve with
the introduction of new formulations and products, advancing the
Company within the expanding multibillion-dollar global market.
TheStockRadio.com Disclosure TheStockRadio.com is not a
registered investment advisor and nothing contained in any
materials should be construed as a recommendation to buy or sell
any securities. TheStockRadio.com is a Web site wholly owned by
Allan James Group. Neither theStockRadio.com nor its affiliates
have a beneficial interest in the mentioned company; nor have they
received compensation of any kind for any of the companies listed
in this communication. Please read our report and visit our Web
site, TheStockRadio.com, for complete risks and
disclosures.
Contact: info@theStockRadio.com
Forward Looking Statements This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing words such as "anticipate," "seek,"
intend," "believe," "plan," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. The Company does not
undertake any duty nor does it intend to update the results of
these forward-looking statements.
Endocan Corporation
President
Dr. Dorothy Bray
info@endocan.com
www.endocan.com
+1.866.326.5595
Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development
robert.kane@endocan.com
+1.561.420.4824
SOURCE Endocan Corporation